Literature DB >> 23092095

Immunoregulation of hepatitis B virus infection--rationale and clinical application.

Tetsuya Ishikawa1.   

Abstract

Hepatitis B virus (HBV) is susceptible to the cellular immune responses, especially to the signal of interferon (IFN)-gamma. The action of IFN-gamma is pleiotropic, and causes downregulation of HBV in protein, RNA, and possibly DNA levels. Therefore, therapeutic vaccination to induce cellular immune responses to HBV is a promising approach for controlling chronic HBV infection. A number of clinical trials with this approach have been conducted to date, however, they have not been as successful as initially expected. T-cell exhaustion induced by the excessive HBV antigens caused by persistent infection is thought to be one of the main causes of poor responses to therapeutic vaccination. In this review, the mechanisms behind immunoregulation of HBV replication and immunodysfunction during chronic HBV infection are summarized, and novel approaches to improve the efficacy of therapeutic vaccination, from basic research to clinical trials, are introduced.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23092095      PMCID: PMC4831231     

Source DB:  PubMed          Journal:  Nagoya J Med Sci        ISSN: 0027-7622            Impact factor:   1.131


  108 in total

Review 1.  PD-1/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection.

Authors:  T Watanabe; A Bertoletti; T A Tanoto
Journal:  J Viral Hepat       Date:  2010-05-10       Impact factor: 3.728

Review 2.  Natural killer cells in viral hepatitis: facts and controversies.

Authors:  Mario U Mondelli; Stefania Varchetta; Barbara Oliviero
Journal:  Eur J Clin Invest       Date:  2010-06-29       Impact factor: 4.686

3.  Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B.

Authors:  Dongping Xu; Junliang Fu; Lei Jin; Hui Zhang; Chunbao Zhou; Zhengsheng Zou; Jing-Min Zhao; Bin Zhang; Ming Shi; Xilai Ding; Zirong Tang; Yang-Xin Fu; Fu-Sheng Wang
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

4.  Autologus dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteers.

Authors:  Jin Luo; Jun Li; Rui L Chen; Lei Nie; Jie Huang; Zheng W Liu; Lin Luo; Xiao J Yan
Journal:  Vaccine       Date:  2010-01-29       Impact factor: 3.641

Review 5.  Antiviral actions of interferons.

Authors:  C E Samuel
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

6.  The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity.

Authors:  David G Bowen; Monica Zen; Lauren Holz; Thomas Davis; Geoffrey W McCaughan; Patrick Bertolino
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

7.  Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B.

Authors:  Renate G van der Molen; Dave Sprengers; Rekha S Binda; Esther C de Jong; Hubert G M Niesters; Johannes G Kusters; Jaap Kwekkeboom; Harry L A Janssen
Journal:  Hepatology       Date:  2004-09       Impact factor: 17.425

8.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

Authors:  C L Lai; R N Chien; N W Leung; T T Chang; R Guan; D I Tai; K Y Ng; P C Wu; J C Dent; J Barber; S L Stephenson; D F Gray
Journal:  N Engl J Med       Date:  1998-07-09       Impact factor: 91.245

9.  Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China.

Authors:  Lihua Ming; Snorri S Thorgeirsson; Mitchell H Gail; Peixin Lu; Curtis C Harris; Nengjin Wang; Yongfu Shao; Zhiyuan Wu; Guoting Liu; Xiaohong Wang; Zongtang Sun
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

10.  Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis.

Authors:  K Ando; T Moriyama; L G Guidotti; S Wirth; R D Schreiber; H J Schlicht; S N Huang; F V Chisari
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

View more
  2 in total

1.  JUNB/AP-1 controls IFN-γ during inflammatory liver disease.

Authors:  Martin K Thomsen; Latifa Bakiri; Sebastian C Hasenfuss; Rainer Hamacher; Lola Martinez; Erwin F Wagner
Journal:  J Clin Invest       Date:  2013-11-08       Impact factor: 14.808

Review 2.  Drug Delivery Strategies for Antivirals against Hepatitis B Virus.

Authors:  Latavia Singh; Sunaina Indermun; Mershen Govender; Pradeep Kumar; Lisa C du Toit; Yahya E Choonara; Viness Pillay
Journal:  Viruses       Date:  2018-05-17       Impact factor: 5.048

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.